Penetrability of intravenous biapenem into the peritoneal fluid of laparotomy patients and the peritoneal pharmacodynamics against gram-negative bacteria

Journal of Applied Research

Volumn 9, Issue 3, 2009, Pages 107-112

  Ikawa, Kazuro ^a   Morikawa, Norifumi ^a   Ikeda, Kayo ^a   Sakashita, Mitsuru ^a   Ohge, Hiroki ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Carbapenem; Infections; Intraabdominal; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BIAPENEM;

ABDOMINAL INFECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG PERITONEAL FLUID LEVEL; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA; LAPAROTOMY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL FLUID; PHARMACODYNAMICS; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 73249116573     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Perry CM, Ibbotson T. Biapenem. Drugs. 2002;62:2221-2234.
2. Mouton JW, Touzw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000;39:185-201.
3. Takata T, Aizawa K, Shimizu A, et al. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J Infect Chemother. 2004;10:76-85.
4. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother. 2001;45:13-22.
5. Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg Infect. 2005;6:329-343.
6. Ikeda K, Ikawa K, Ikeda A, et al. A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;844:148-152.
7. Yamaoka K, Tanigawara Y, Nakagawa T, et al. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981;4:879-885.
8. Ikawa K, Morikawa N, Hayato S, et al. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int J Antimicrob Agents. 2007;30:270-273.
9. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother. 2005;55:965-973.
10. Yamaguchi K, Murakami M, Takahashi A, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Jpn J Antibiot. 2005;58:655-689.
11. Yamaguchi K, Ishii Y, Iwata M, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn J Antibiot. 2007;60:344-377.
12. Ikawa K, Morikawa N, Sakamoto K, et al. Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients. Chemotherapy. 2008;54:131-139.
13. Ikawa K, Morikawa N, Urakawa N, et al. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother. 2007;60:1395-1397.
14. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67:1027-1052.
15. Kotapati S, Kuti JL, Nicolau DP. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Surg Infect. 2005;6:297-304.
16. Eagye KJ, Kuti JL, Dowzicky M, et al. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther. 2007;29:889-899.